Bart L. Scott, MD, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses breakthrough topics in myelodysplastic syndromes (MDS), such as mutational abnormalities.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More